Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01211639 · ClinicalTrials.gov registry record
Genetic Evaluation of Natalizumab-Treated Patients With Progressive Multifocal Leukoencephalopathy
A clinical trial, sponsored by Biogen.
- Terminated
- Registry status
- 24
- Enrollment target
NCT01211639 is a clinical trial that was terminated before completion, run by Biogen. The registered enrollment target is 24 participants.
The verdict
NCT01211639 was terminated before completion, sponsored by Biogen.
- TERMINATED
- Registry status
- 24 participants
- Enrollment target
Study Summary
The purpose of this study is to explore host genetic mutations which may render individual subjects more susceptible (or resistant) to developing Progressive Multifocal Leukoencephalopathy (PML). Samples will also be collected to determine Deoxyribonucleic Acid (DNA) sequence of JC Virus (JCV). Analysis of the JC Virus (JCV) genome may provide information about viral genotypes that may be associated with higher pathogenicity, and help to identify individuals who may be at higher risk of developing Progressive Multifocal Leukoencephalopathy (PML) due to chronic infection with a more pathogenic variant of JC Virus (JCV).
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2010-10 |
| Est. Completion | 2014-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01211639
The ClinicalTrials.gov registry entry for NCT01211639 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01211639 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01211639 about?
NCT01211639 is a clinical study titled "Genetic Evaluation of Natalizumab-Treated Patients With Progressive Multifocal Leukoencephalopathy". The purpose of this study is to explore host genetic mutations which may render individual subjects more susceptible (or resistant) to developing Progressive Multifocal Leukoencephalopathy (PML). Samples will also be collected to determine Deoxyribonucleic Acid (DNA) sequence of JC Virus (JCV). Anal...
What is the current status of trial NCT01211639?
This trial is currently terminated. The enrollment target is 24 participants. The study started on 2010-10. Estimated completion is 2014-08.
Who is sponsoring clinical trial NCT01211639?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.